IBIO123

BIOLOGICAL3 trials

Sponsors

Immune Biosolutions Inc

Conditions

COVID-19

Phase 1

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

CompletedNCT05298813

Immune Biosolutions IncCOVID-19

Start: 2021-09-29End: 2023-01-04Updated: 2023-05-01

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

CompletedNCT05303376

Immune Biosolutions IncCOVID-19

Start: 2022-02-22End: 2023-06-27Updated: 2023-09-13

Phase 2

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

CompletedNCT05639166

Immune Biosolutions IncCOVID-19

Start: 2023-02-18End: 2023-05-16Updated: 2023-05-22

Related Papers

Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.

2023-08-2111 citations